Prior Authorization Legislation Takes Center Stage at Joint Hearing on Health Care Affordability
A joint hearing held on Jan. 22 by the U.S. House of Representatives Energy & Commerce Subcommittee on Health and the Ways and Means Committee hosted...
1 min read
Legislators and pathologists alike are expressing opposition to the final rule from the U.S. Food and Drug Administration regulating laboratory-developed tests (LDTs) as medical devices.
On Feb. 21, U.S. Reps. Brad Finstad (R-Minn.) and Dan Crenshaw (R-Texas) introduced legislation that would effectively reverse the final rule. The Freedom for Laboratory Innovation and Testing Act would prohibit the use of federal funding to implement and enforce the LDT final rule.
Finstad and Crenshaw also cosigned a letter to U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., calling for the rule to be revoked, “allowing Congress to examine the issue and determine any necessary regulatory changes.”
The Association for Molecular Pathology, a plaintiff in the pending lawsuit against the FDA over the rule, is listed among the organizations that support the legislation. Meanwhile, the College of American Pathologists (CAP) on Feb. 14 sent a letter to Kennedy urging the administration to terminate the LDT rule in keeping with the executive order “Unleashing Prosperity Through Deregulation,” signed by the president on Jan. 31. The CAP is requesting HHS works with Congress to enact legislation that establishes a regulatory framework specifically for LDTs.
Sources:
https://documents.cap.org/documents/CAP_letter_Kennedy_Confirmation_FNL_2025.pdf
Payer Update for Blue Cross Blue Shield New Jersey
TELCOR has identified ongoing processing challenges with BCBS New Jersey that laboratories should be aware of. When claims require medical records,...
Payer Update for BCBS Nebraska
TELCOR has identified a recent process change with BCBSNebraska impacting payment timelines. As of November 1, 2025, BCBSNE adjustedits payment...